TABLE 2

Cross-reactivity of antibodies from four groups of human patient serum specimens against ZIKV and DENV-2/3 wt VLP and NS1 antigens

Serum panel (no. of samples)No. cross-reactive/total no. tested (%)a
ZIKV-wt-VLP-MAC-ELISAZIKV-NS1-MAC-ELISADENV2/3-wt-VLP-MAC-ELISAbDENV2-NS1-MAC-ELISA
ZIKV (21)21/21 (100)21/21 (100)20/21 (95.2)*12/21 (57.1)*
    Acute (23)16/23 (69.6)16/23 (69.6)22/23 (95.7)**2/23 (8.7)**
    Convalescent (19)18/19 (94.7)19/19 (100)19/19 (100)***10/19 (52.6)***
WNV (56)2/56 (3.6)0/56 (0)NANA
DENV (44)28/44 (63.6)32/44 (72.7)42/44 (95.5)40/44 (90.9)
    Acute (40)17/40 (42.5)25/40 (62.5)26/40 (65.0)23/40 (57.5)
    Convalescent (42)23/42 (54.8)24/42 (57.1)40/42 (95.2)38/42 (90.5)
Other (76)0/76 (0)0/76 (0)0/76 (0)2/76 (2.6)
  • a NA, not available. *, P = 0.0042, with significance level at 0.05; **, P < 0.0001, with significance level at 0.05; ***, P = 0.0007, with significance level at 0.05.

  • b The cutoff for DENV-2/3 VLP or NS1-MAC-ELISA was based on our previous publication (24).